Clinical-Grade Natural CDMO & CRO Solutions

ODM Phase IV Trials Manufacturers & Supplier Real-World Evidence Modernization

Accelerate botanical, TCM, and natural pharmaceutical post-market surveillance. MedGence pairs standardized phytochemical quality profiling with end-to-end multi-center Phase IV registry networks and regulatory-ready Pharmacovigilance.

Validated CRO/CDMO Frameworks

Integrated R&D and Preclinical-to-Clinical Programs

Explore our flagship translational research modules supporting botanical active screening, bioassay standardization, and Phase I–IV clinical validation.

Industry Paradigm Shift

Phase IV Post-Marketing Trials in Botanical Drug & Health Formulation Development

The transition from empirical botanical therapies to modern evidence-driven health systems demands empirical verification in real-world patient cohorts.

Real-World Evidence (RWE) Integration

Global regulatory agencies—including the US FDA, EMA, and NMPA—increasingly require Phase IV Post-Marketing Surveillance and observational registries to confirm safety signals in heterogeneous populations, expanding beyond restricted Phase III eligibility.

Label Expansion & Reimbursement Support

Phase IV data validates comparative effectiveness against chemical standards of care. This supports health economics and outcomes research (HEOR), enabling botanical candidates to secure hospital formulary tiering and insurance reimbursements.

Traceable Botanical Pharmacovigilance

Multi-component phytomedicines present complex drug-herb interactions. Advanced Phase IV systems monitor patient cohorts over long treatment horizons, isolating rare adverse events and verifying lot-to-lot bioequivalence at scale.

Proven Research Track Record

Engineered Scale in Clinical & Phytochemical Execution

Combining 14+ years of specialized CRO/CDMO services with institutional clinical ties across China’s premier hospitals.

14+
Years in Phytomedicine CRO/CDMO
300+
Ph.D. Scientists & Researchers
83
Classic TCM Formulas Modernized
56
Hospital Preparations Registered
22
Innovative Natural Drugs Developed
~400
Herb Quality Standards Established
100+
Pharmaceutical Groups Served
100%
Proprietary IP & Data Protection
Sourcing & Procurement Insights

Addressing Enterprise Procurement Pain Points in Phase IV Alliances

Global pharmaceutical executives, sourcing directors, and brand developers require partners that bridge raw chemistry with compliant post-marketing clinical oversight.

Challenge: Chemical Variability

Uncontrolled botanical variations between harvest origins alter bioactivity, skewing multicenter Phase IV results and inviting regulatory non-compliance.

  • Our Solution: Chemotaxonomic fingerprinting (HPTLC, HPLC-MS, GC).
  • Standardized active reference marker tracking across commercial batches.

Challenge: Clinical Attrition & Site Delays

Post-market trials often suffer from delayed subject enrollment, decentralized data loss, and protocol divergence across regional medical institutions.

  • Our Solution: Direct access to tier-3 hospital trial centers.
  • Integrated Electronic Data Capture (EDC) adhering to CDISC clinical standards.

Challenge: IP Leakage in ODM Transfer

Transferring pilot studies into full-scale industrial dosage manufacturing risks recipe leaks and formulation compromise.

  • Our Solution: Entrusted contract model with ironclad NDA covenants.
  • In-house pilot facilities transitioning seamlessly to commercial finished lines.
Global Compliance Framework

Regulatory Cross-Walk & Localized Governance

Phase IV post-marketing generation engineered to conform with international pharmacopeia and regulatory health agency audits.

ICH-GCP Alignment

Every clinical project is executed under stringent International Council for Harmonisation (ICH) Good Clinical Practice guidelines. Clinical research associates (CRAs) conduct on-site audits, ensuring absolute source document verification (SDV).

Pharmacovigilance & CIOMS

Automated safety alerting channels ensure real-time adverse drug reaction (ADR) triage, preparing periodic safety update reports (PSUR) and Individual Case Safety Reports (ICSR) matching FDA MedWatch and EMA EudraVigilance criteria.

cGMP Formulation Parity

Clinical batches for Phase IV comparative effectiveness and real-world compliance testing are produced in certified cGMP facilities—available in softgels, tablets, oral liquids, and encapsulated granulates.

Methodological Roadmap

The Next-Gen Phase IV Clinical Pipeline: 2025–2030

How artificial intelligence, digital biomarkers, and decentralized registries are shortening post-market trial durations.

Phase 01

AI-Powered Cohort Screening

Natural Language Processing parsing electronic health records (EHR) to identify targeted patient populations matching complex inclusion criteria.

Phase 02

Decentralized Monitoring

Wearable biosensors and mobile health interfaces capturing continuous patient biomarkers to evaluate functional quality-of-life parameters.

Phase 03

Multi-Omics Mechanistic Validation

Metabolomics and microbiome profiling mapped against post-treatment clinical changes, revealing clear polychemical mechanisms of action.

Phase 04

Automated Dossier Generation

Algorithmically unified real-world databases compiled into eCTD format for rapid health-authority label extensions and health insurance inclusion.

Hospital Alliances & Enterprise Clients

Validated in Collaboration with 33 Leading Institutions

Our research frameworks are trusted by national TCM research hospitals and Fortune 500 pharmaceutical conglomerates.

Beijing Tongrentang GroupTongrentang Group
China Resources SanjiuCR Sanjiu Pharma
Sunflower Pharmaceutical GroupSunflower Pharma
Livzon Pharmaceutical GroupLivzon Pharma Group
Dihon Pharmaceutical GroupDihon Pharma
Golden Throat HoldingsGolden Throat Holdings
Yangtzi River Pharmaceutical GroupYangtzi River Pharma
Beihai Gofar Chuanshan BiologicalBeihai Gofar Bio
Humanwell HealthcareHumanwell Healthcare
SCIMYTH Pharmaceutical GroupSCIMYTH Pharma
Shandong Hanfang PharmaceuticalShandong Hanfang
Luoxin Pharmaceutical GroupLuoxin Pharma
Guangdong Zhongsheng PharmaceuticalZhongsheng Pharma
Hunan Brilliance & Abundance ScientificHunan Brilliance TCM
Apeloa PharmaceuticalApeloa Pharma
Hunan Heng Chang PharmaceuticalHeng Chang Pharma
Baotou Traditional Chinese MedicineBaotou TCM
Kamp Medicine Co.Kamp Medicine
Guangxi Santo PharmaceuticalGuangxi Santo
Hunan Kangshou PharmaceuticalHunan Kangshou
Jiangxi Juwang PharmaceuticalJiangxi Juwang
Beijing Tcmages PharmaceuticalBeijing Tcmages
Guizhou Ruihe PharmaceuticalGuizhou Ruihe
Anhui CR Jinchan PharmaceuticalCR Jinchan Pharma
Kangmei PharmaceuticalKangmei Pharma
Hunan Tianjicaotang PharmaceuticalTianjicaotang Pharma
Jiangxi Kingstone Unite PharmaceuticalKingstone Unite
Shuguang Hospital Affiliated to Shanghai TCMShuguang Hospital
Hunan Directly Affiliated TCM HospitalHunan TCM Hospital
First Hospital of Hunan University of CMFirst Hosp Hunan TCM
Second Xiangya Hospital Central South UnivSecond Xiangya Hospital
Second Hospital of Hunan University of CMSecond Hosp Hunan TCM
Orthopedics of TCM Zhuzhou CityZhuzhou TCM Orthopedics
Technical & Commercial FAQ

Frequently Asked Questions on ODM Phase IV Trials & CDMO Supply

In-depth responses for procurement leaders, Chief Medical Officers, and regulatory strategists.

What defines an ODM Phase IV Clinical Trial in botanical & natural medicine?
An ODM (Original Design Manufacturer) Phase IV Trial is an integrated arrangement where MedGence designs the formulation, establishes chemical fingerprint standardization, and executes the prospective or observational post-marketing clinical trial under our unified research protocols. This provides pharmaceutical partners with complete evidence packages for market expansion, pharmacovigilance, or health-claim defense without managing separate research, lab testing, and clinical vendors.
How does MedGence handle batch-to-batch botanical chemical consistency for multicenter trials?
We isolate variability at the botanical source. Our labs evaluate origin, harvest season, and plant parts using high-performance thin-layer chromatography (HPTLC), HPLC assay, and GC fingerprinting. By mapping reference marker standards, we ensure clinical trial batches supplied for Phase IV studies strictly match the exact compositional fingerprint used in foundational efficacy safety dossiers.
Can Phase IV real-world data support dietary supplement claims in international markets?
Yes. Major markets such as the US (FTC/FDA substantiation guidelines) and Europe (EFSA claims requirements) mandate competent and reliable scientific evidence. Well-documented Phase IV registries and small-to-large cohort human observational trials provide the gold standard for substantiating structure/function claims and protecting products against regulatory challenges.
How is intellectual property and proprietary formulation know-how preserved?
We work exclusively under legally binding entrusted contract research structures. Every formula detail, analytical fingerprint, raw material extraction parameter, and clinical dataset is guarded under comprehensive non-disclosure agreements (NDAs) and transferred directly to your organization upon project completion. MedGence maintains no external marketing rights to your bespoke formulations.
Which dosage forms can your integrated CDMO infrastructure deliver?
We support botanical active supply in concentrated liquids, purified spray-dried powders, pastes, and refined volatile essential oils. For finished clinical and retail presentations, our cGMP partner plants supply hard capsules, softgels, tableted cores, oral liquids, effervescent granules, and standardized soluble powders.
What clinical registry documentation is provided upon trial closeout?
Our clinical deliverables include complete ICH-E3 compliant Clinical Study Reports (CSR), locked statistical analysis datasets (SAS/CDISC SDTM & ADaM formats), institutional ethics committee (IRB/IEC) approval records, verified pharmacovigilance safety summaries, and peer-reviewed manuscript drafts for journal publication.
Commercial Formulation & Manufacturing

Order Validated Active Extracts & Specialized Clinical Formulations

Direct supply contracts backed by complete physicochemical dossiers and multi-phase clinical safety files.